NCT04448340: MLDLB

A Novel Machine Learning Algorithm to Predict the Lewy Body Dementias

Status unknown Last updated 10 September 2020

What this trial tests

trial testing machine learning model in Dementia in 200 participants. Status unknown.

Timeline

1 September 2019

Primary endpoint
1 October 2020

1 March 2021

Quick facts

Lead sponsor	National and Kapodistrian University of Athens
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 September 2019
Primary completion	1 October 2020
Estimated completion	1 March 2021
Sites	1 location across Greece

Drugs / interventions tested

• machine learning model

Conditions studied

• Dementia — all drugs for Dementia →

Sponsor

National and Kapodistrian University of Athens

Who can join

Adults 50 to 90, any sex, with Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parkinson's disease dementia (PDD) and Dementia with lewy bodies (DLB) are dementia syndromes that overlap in many clinical features, making their diagnosis difficult in clinical practice, particularly in advanced stages. We propose a machine learning algorithm, based only on non-invasively and easily in-the-clinic collectable predictors, to identify these disorders with a high prognostic performance.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. A Novel Machine Learning Algorithm Predicts Dementia With Lewy Bodies Versus Parkinson's Disease Dementia Based on Clinical and Neuropsychological Scores.
   Bougea A, Efthymiopoulou E, Spanou I, Zikos P. · · 2022 · cited 9× · PMID 33550890 · DOI 10.1177/0891988721993556
2. Amantadine improves executive and memory functions in patients with Parkinsons Disease: Double blind parallel two-arm randomized controlled trial
   Bougea A, Efthymiopoulou Ε, Degirmenci Y, Zikos P. · · 2025 · DOI 10.21203/rs.3.rs-7142916/v1